Friday, 6 November 2026European Markets

ELKEM And ALTRI SGPS Have A High Dividend Yield And Return On Equity In The Basic Materials Sector.

Loading stream...

(VIANEWS) - ELKEM (ELK.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Basic Materials sector.

Financial Asset Price Forward Dividend Yield Return on Equity
ELKEM (ELK.OL) kr20.74 25.91% 19.37%
ALTRI SGPS (ALTR.LS) €5.26 4.85% 8.22%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ELKEM (ELK.OL)

25.91% Forward Dividend Yield and 19.37% Return On Equity

Elkem ASA engages in the provision of advanced material solutions worldwide. It operates through three segments: Silicones, Silicon Products, and Carbon Solutions. The company offers silicones polymers, including silicone oils, compounds, emulsions, grease, and resins, as well as chlorosilanes, heat cured rubber silicone, liquid silicone rubber, and RTV-1 and RTV-2 silicones. It also provides silicon-based materials comprising silicon, silicon powder/micronized silicon, silica fume/ micro-silica, ferrosilicon, and grain refiners. In addition, the company offers foundry alloys, such as preconditioners, recarburizers, conditioners, nodularizers, inserts, and inoculants; and carbon-based materials comprising carbon electrodes, furnace tapping materials, electrode paste, ramming paste, prebaked electrodes, and furnace lining materials, as well as polymer additives, and oilfield and refractories specialty products. It offers its products to electronics, aerospace, healthcare, personal care, packaging, airbag coating, chemicals, aluminium, electronics, automotive, specialty steel, solar, construction, refractories, oil and gas, ferroalloys, silicon, and aluminium industries. The company was founded in 1904 and is headquartered in Oslo, Norway. Elkem ASA operates as a subsidiary of Bluestar Elkem International Co., Ltd. S.A.

Earnings Per Share

As for profitability, ELKEM has a trailing twelve months EPS of kr-2.08.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.37%.

Moving Average

ELKEM's worth is way under its 50-day moving average of kr24.60 and way under its 200-day moving average of kr32.12.

Earnings Before Interest, Taxes, Depreciation, and Amortization

ELKEM's EBITDA is 0.58.

More news about ELKEM.

2. ALTRI SGPS (ALTR.LS)

4.85% Forward Dividend Yield and 8.22% Return On Equity

Altri, SGPS, S.A. produces and sells cellulosic fibers and energy in Portugal and internationally. The company produces pulp products for various application including production of paper, tissue, and printing and writing papers; and dissolving pulp for use of textile production. It is also involved timber commercialization; forest management; production of forest-based renewable energy, such as industrial cogeneration from black liquor and biomass; real estate activities; and production of plants in nurseries, as well as the provision of services related with forests and landscapes. The company was incorporated in 2005 and is headquartered in Porto, Portugal.

Earnings Per Share

As for profitability, ALTRI SGPS has a trailing twelve months EPS of €0.21.

PE Ratio

ALTRI SGPS has a trailing twelve months price to earnings ratio of 25.05. Meaning, the purchaser of the share is investing €25.05 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.22%.

More news about ALTRI SGPS.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com